Analysis of sorafenib starting dose and outcomes from the European subset of GIDEON (Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of its Treatment with Sorafenib SOR ) in > 1000 patients (pts)
![Thumbnail](/xmlui/themes/Mirage2//images/thumbnails/thumn_cientif.png)
Fecha de publicación
2013Título de revista
EUROPEAN JOURNAL OF CANCER
Tipo de contenido
Publicación de congreso
![](/xmlui/themes/Mirage2//images/final_lines.png)